The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
ARDS - Acute lung injury
Publications
Pulmonary toxicity of recombinant interleukin-2 plus lymphokine-activated killer cell therapy.
The European respiratory journal 1993 Jun;6;828-33 — 1993 Jun — 828-33
Negrier MS, Pourreau CN, Palmer PA, Ranchere JY, Mercatello A, Viens P, Blaise D, Jasmin C, Misset JL, Franks CR
Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992 Feb;11;93-102 — 1992 Feb — 93-102